Phase 1 Multicenter Study of Multiple Doses of Rhenium (186Re) Obisbemeda (Reyobiq) for Leptomeningeal Metastases: Rationale, Design, and Preliminary Cohort 1 Data (SNO 2025) - Dec 2, 2025 - Abstract #CTNI-67; Pres time: Nov 21, 2025; 11:30 AM - 12:45 PM; Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III; P1 | "Cohort 1 data, including safety and preliminary efficacy, will be presented. This study builds on single-dose findings, aiming to optimize dosing regimens to improve outcomes for LM patients, addressing an unmet clinical need with a novel radiotherapeutic approach."
Clinical • P1 data • Hematological Disorders • Solid Tumor • Thrombocytopenia
|
|
Andrew Brenner; Priya Kumthekar; Michael Schulder; Eva Galvan; Ande Bao; Joel Michalek; Penny Vroman; William Phillips; John Floyd; Jonathan T. Yang; Michael Rosol; Marc Hedrick; Michael Youssef
|